The National Heart, Lung, and Blood Institute convened an expert panel April 28 to 29,
2008, to identify gaps and recommend research strategies to prevent atrial fibrillation (AF) …

Background and Purpose—Embolic stroke of undetermined source (ESUS) designates
patients with nonlacunar cryptogenic ischemic strokes in whom embolism is the likely stroke …

placebo-controlled studies. Nonetheless, amiodarone is approved for use against VT and
VF by most regulatory agencies worldwide and has a high profile as a useful drug. 21 Its …

Background Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases
the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin …

Background Vitamin K antagonists have been shown to prevent stroke in patients with atrial
fibrillation. However, many patients are not suitable candidates for or are unwilling to receive …

Background We evaluated whether rivaroxaban alone or in combination with aspirin would
be more effective than aspirin alone for secondary cardiovascular prevention. Methods In …

Background It is common practice to restore and maintain sinus rhythm in patients with atrial
fibrillation and heart failure. This approach is based in part on data indicating that atrial …

Background One quarter of strokes are of unknown cause, and subclinical atrial fibrillation
may be a common etiologic factor. Pacemakers can detect subclinical episodes of rapid …

Background Dabigatran is an oral direct thrombin inhibitor that has been shown to be an
effective alternative to warfarin in patients with atrial fibrillation. We evaluated the use of …

Background—Patients surviving ventricular fibrillation (VF) or sustained ventricular
tachycardia (VT) are at a high risk of death due to a recurrence of arrhythmia. The …